(Total Views: 561)
Posted On: 07/01/2022 3:58:22 PM
Post# of 154115
Risankizumab is an IL-23a inhibitor. Leronlimab is a superior anti-inflammatory which controls many of the activators of IL-23a in addition to other inflammatory factors.
Risankizumab has serious adverse events in 7.8% of patients so leronlimab has a far superior safety profile.
Crohn's Disease is one of the first diseases that I looked at because a friend has it and it's debilitating.
A paper if anyone wants to take a look.
Risankizumab has serious adverse events in 7.8% of patients so leronlimab has a far superior safety profile.
Crohn's Disease is one of the first diseases that I looked at because a friend has it and it's debilitating.
A paper if anyone wants to take a look.
Quote:
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974621/
(10)
(0)
